Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DC-CIK Treatment in Stage III Colorectal Cancer
NCT01839539Phase 2Unknown
- Sponsor
- Guangxi Medical University
- Start
- Mar 2013
- Primary completion
- Mar 2018
- Modality
- Prophylactic Vaccines, Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in colorectal cancer (CRC) comparing DC-CIK Group with Observation Group (2 arms). Primary endpoint: Progression-Free Survival at 5 years. Status: unknown.
02
Drugs
dendritic cell vaccine + cytokine-induced killer cells
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT01839539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01839539.